This paper is only available as a PDF. To read, Please Download here.
Results from the National Cancer Institute (Bethesda, U.S.A.) showed that Ukrain (NSC
631570) has on human colorectal cell culture lines a more than 100-fold higher cytotoxic
activity than broadly used 5fluorouracil (NSC 19893). In the EORTC study Ukrain was
toxic to the colorectal cell lane CXF. That date gave us the basis for the next clinical
study. In a randomised study 108 patients with advanced colorectal cancer, average
61.2 years, were included. 54 patients were treated with Ukrain as monotherapy and
54 with 5-fluororacil. The therapy results (clinical, haematological, immunological,
biochemical) show that Ukrain has favourable properties in the treatment of colorectal
cancer and clearly show advantages in contrary to 5-fluorouracil. Stability of the
disease was reached in 88.8% and only 27.7% in the control group. The pretreatment
with Ukrain facilitated the operability of the patients. The malignotoxic action of
Ukrain in the clinic is confirmed by the results of pathomorphosis that gives more
possibilities in operative treatment and increases the survival rate. Ukrain is a
new effective drug in the therapy of colorectal cancer.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 1995 Elsevier Science Ltd. Published by Elsevier Inc. All rights reserved.
